Your Article Summary
See Latest ArticlesOnce-yearly Aclasta approved in EU to treat osteoporosis caused by steroid treatment in men and postmenopausal women
Novartis, 06/29/09
Once-yearly Aclasta has been approved in the European Union to treat men and postmenopausal women with osteoporosis caused by long-term use of glucocorticoids, commonly known as steroids. Glucocorticoids are widely used to treat inflammatory conditions such as asthma and rheumatoid arthritis, but also cause bone loss and can increase the risk of fracture in up to 50% of patients on long-term glucocorticoid therapy.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of Patent Ductus Arteriosus: Indomethacin or Ibuprofen
American Journal of Perinatology, 12/18/09
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
International Journal of Women's Health, 12/18/09
Dienogest: a new therapeutic agent for the treatment of endometriosis
Women's Health, 12/17/09
Today in Menopausal Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
International Journal of Women's Health, 12/18/09
Postmenopausal Hormone Therapy Increases Retinal Blood Flow and Protects the Retinal Nerve Fiber Layer
Investigative Ophthalmology and Visual Science, 12/18/09
Effect of genistein therapy on plasma levels of asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study
Fertility and Sterility, 12/16/09